Analyzing iRadimed (NASDAQ:IRMD) and Enovis (NYSE:ENOV)

Enovis (NYSE:ENOV) and iRadimed (NASDAQ:IRMD) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, dividends, valuation and analyst recommendations.

Insider & Institutional Ownership

98.5% of Enovis shares are owned by institutional investors. Comparatively, 92.3% of iRadimed shares are owned by institutional investors. 2.9% of Enovis shares are owned by insiders. Comparatively, 34.6% of iRadimed shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and recommmendations for Enovis and iRadimed, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enovis	1	1	10	0	2.75
iRadimed	0	2	3	1	2.83

Enovis presently has a consensus price target of $37.25, indicating a potential upside of 76.83%. iRadimed has a consensus price target of $120.00, indicating a potential upside of 39.83%. Given Enovis’ higher possible upside, equities analysts clearly believe Enovis is more favorable than iRadimed.

Profitability

This table compares Enovis and iRadimed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Enovis	-47.96%	12.03%	4.91%
iRadimed	26.70%	23.45%	20.36%

Volatility and Risk

Enovis has a beta of 1.37, indicating that its share price is 37% more volatile than the S&P 500. Comparatively, iRadimed has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500.

Earnings and Valuation

This table compares Enovis and iRadimed”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enovis	$2.25 billion	0.54	-$1.18 billion	($19.26)	-1.09
iRadimed	$83.81 million	13.10	$22.48 million	$1.79	47.94

iRadimed has lower revenue, but higher earnings than Enovis. Enovis is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.

Summary

iRadimed beats Enovis on 10 of the 15 factors compared between the two stocks.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.

About iRadimed

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.